Novogen Announces New Executive Service Agreements
March 31, 2010 08:00 ET
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - March 31, 2010) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) advises that it has entered into new executive service agreements with its seven most senior executives.
...
Marshall Edwards, Inc. Announces Stockholder Approval and Implementation of 1:10 Reverse Stock Split
March 31, 2010 08:00 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - March 31, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
Marshall Edwards, Inc. Receives Nasdaq Staff Determination
March 19, 2010 08:00 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - March 19, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics,...
Marshall Edwards, Inc.'s Action Intended to Regain Compliance With Nasdaq Share Price Rule, Benefit Shareholders
February 09, 2010 15:30 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - February 9, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics,...
Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors
February 08, 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA--(Marketwire - February 8, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL)
announced that Christopher Naughton had resigned as a member of the Board
of Directors effective February 5,...
Analysis of Marshall Edwards, Inc.'s OVATURE Trial to Proceed Following Database Lock
January 21, 2010 18:34 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - January 21, 2010) - The Board of Directors of Marshall Edwards,
Inc. today advised that analysis of tumor response data from the OVATURE
trial will be performed in the...
Marshall Edwards, Inc. Appoints Acting CEO
December 01, 2009 00:01 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - December 1, 2009) - Novogen Limited
advises that CEO and Managing Director Christopher Naughton will cease his
employment with the Company from...
Marshall Edwards, Inc.'s NV-128, a Novel mTOR Inhibitor, Demonstrates Good Safety Profile and High Anti-Cancer Activity In Vivo
September 29, 2009 08:30 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - September 29, 2009) - Marshall Edwards, Inc.
(NASDAQ: MSHL), a pharmaceutical company specializing in clinical
development of oncology drugs, today...
Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance
September 22, 2009 09:03 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - September 22, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL), a
specialist oncology company focusing on the clinical development of novel
anti-cancer therapeutics, today...
WHITECOAT Strategies and Comprendia Sign Strategic Partnership Agreement to Better Target Key Opinion Leaders, Patients, and Advocates
August 12, 2009 08:00 ET
|
WHITECOAT Strategies
WASHINGTON, DC and SAN DIEGO, CA--(Marketwire - August 12, 2009) - WHITECOAT Strategies, a
public relations firm specializing in the use of new media and online video
for clients with innovative...